Rotavirus vaccine effectiveness and impact in Uzbekistan, the first country to introduce in central Asia

Uzbekistan, the most populous country in central Asia, was the first in the region to introduce rotavirus vaccine into its national immunization program. Rotarix (GlaxoSmithKline Biologicals, RV1) was introduced in June 2014, with doses recommended at age 2 and 3 months. To evaluate vaccine impact,...

詳細記述

書誌詳細

主要な著者:	Umid Eraliev, Renat Latipov, Dilorom Tursunova, Annemarie Wasley, Danni Daniels, Umed Ismoilov, Manzura Akramova, Mehri Sultanova, Dilbar Yuldashova, Bahodir Barakaev, Vazira Mutalova, Laziz Tuychiev, Erkin Musabaev, Said Sharapov, Boris Pleshkov, Dovile Videbaek, Shahin Huseynov, Kamola Safaeva, Slavica Mijatovic-Rustempasic, Michael D. Bowen, Umesh D. Parashar, Margaret M. Cortese
フォーマット:	Artigo
言語:	Inglês
出版事項:	Taylor & Francis Group 2021-02-01
シリーズ:	Human Vaccines & Immunotherapeutics
主題:	rotavirus vaccine uzbekistan rotavirus vaccine effectiveness vaccine impact children
オンライン･アクセス:	http://dx.doi.org/10.1080/21645515.2020.1776034
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!